111 related articles for article (PubMed ID: 28139838)
1. Rolapitant Absolute Bioavailability and PET Imaging Studies in Healthy Adult Volunteers.
Wang X; Zhang ZY; Powers D; Wang J; Lu S; Kansra V
Clin Pharmacol Ther; 2017 Aug; 102(2):332-339. PubMed ID: 28139838
[TBL] [Abstract][Full Text] [Related]
2. Bioequivalence of Intravenous and Oral Rolapitant: Results From a Randomized, Open-Label Pivotal Study.
Wang X; Zhang ZY; Powers D; Wang J; Lu S; Arora S; Hughes L; Christensen J; Kansra V
J Clin Pharmacol; 2017 Dec; 57(12):1600-1606. PubMed ID: 28906561
[TBL] [Abstract][Full Text] [Related]
3. Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects.
Zhang ZY; Wang J; Kansra V; Wang X
Invest New Drugs; 2019 Feb; 37(1):139-146. PubMed ID: 30032410
[TBL] [Abstract][Full Text] [Related]
4. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant.
Bergström M; Hargreaves RJ; Burns HD; Goldberg MR; Sciberras D; Reines SA; Petty KJ; Ogren M; Antoni G; Långström B; Eskola O; Scheinin M; Solin O; Majumdar AK; Constanzer ML; Battisti WP; Bradstreet TE; Gargano C; Hietala J
Biol Psychiatry; 2004 May; 55(10):1007-12. PubMed ID: 15121485
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
6. Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers.
Wang X; Zhang ZY; Arora S; Hughes L; Wang J; Powers D; Christensen J; Lu S; Kansra V
J Clin Pharmacol; 2018 Feb; 58(2):202-211. PubMed ID: 28906558
[TBL] [Abstract][Full Text] [Related]
7. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.
Chasen MR; Rapoport BL
Future Oncol; 2016 Mar; 12(6):763-78. PubMed ID: 26842387
[TBL] [Abstract][Full Text] [Related]
8. Rolapitant for the prevention of delayed nausea and vomiting over initial and repeat courses of emetogenic chemotherapy.
Rapoport B; van Eeden R; Smit T
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):17-29. PubMed ID: 27894202
[TBL] [Abstract][Full Text] [Related]
9. Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET.
Ridler K; Gunn RN; Searle GE; Barletta J; Passchier J; Dixson L; Hallett WA; Ashworth S; Gray FA; Burgess C; Poggesi I; Bullman JN; Ratti E; Laruelle MA; Rabiner EA
J Psychopharmacol; 2014 Mar; 28(3):244-53. PubMed ID: 24429221
[TBL] [Abstract][Full Text] [Related]
10. Quantification of central substance P receptor occupancy by aprepitant using small animal positron emission tomography.
Endo T; Saijo T; Haneda E; Maeda J; Tokunaga M; Zhang MR; Kannami A; Asai H; Suzuki M; Suhara T; Higuchi M
Int J Neuropsychopharmacol; 2014 Oct; 18(2):. PubMed ID: 25609595
[TBL] [Abstract][Full Text] [Related]
11. Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV).
Rashad N; Abdel-Rahman O
Drug Des Devel Ther; 2017; 11():947-954. PubMed ID: 28392676
[TBL] [Abstract][Full Text] [Related]
12. An Open-Label, Randomized, Pivotal Bioequivalence Study of Oral Rolapitant.
Zhang ZY; Wang J; Arora S; Lu S; Powers D; Kansra V; Wang X
Clin Pharmacol Drug Dev; 2019 Feb; 8(2):152-159. PubMed ID: 30624856
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment.
Wang J; Wang X; Zhang ZY; Arora S; Lu S; Kansra V
J Clin Pharmacol; 2018 May; 58(5):686-693. PubMed ID: 29329482
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, Safety, and Tolerability of Rolapitant Administered Intravenously Following Single Ascending and Multiple Ascending Doses in Healthy Subjects.
Wang X; Zhang ZY; Wang J; Powers D; Arora S; Lu S; Kansra V
Clin Pharmacol Drug Dev; 2019 Feb; 8(2):160-171. PubMed ID: 29905976
[TBL] [Abstract][Full Text] [Related]
15. Rolapitant: first global approval.
Syed YY
Drugs; 2015 Nov; 75(16):1941-5. PubMed ID: 26467681
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
Rojas C; Slusher BS
Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
[TBL] [Abstract][Full Text] [Related]
17. Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets.
Duffy RA; Morgan C; Naylor R; Higgins GA; Varty GB; Lachowicz JE; Parker EM
Pharmacol Biochem Behav; 2012 Jul; 102(1):95-100. PubMed ID: 22497992
[TBL] [Abstract][Full Text] [Related]
18. Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging.
Van Laere K; De Hoon J; Bormans G; Koole M; Derdelinckx I; De Lepeleire I; Declercq R; Sanabria Bohorquez SM; Hamill T; Mozley PD; Tatosian D; Xie W; Liu Y; Liu F; Zappacosta P; Mahon C; Butterfield KL; Rosen LB; Murphy MG; Hargreaves RJ; Wagner JA; Shadle CR
Clin Pharmacol Ther; 2012 Aug; 92(2):243-50. PubMed ID: 22739139
[TBL] [Abstract][Full Text] [Related]
19. A Phase 1 Assessment of the QT Interval in Healthy Adults Following Exposure to Rolapitant, a Cancer Supportive Care Antiemetic.
Wang X; Zhang ZY; Wang J; Kansra V
Clin Pharmacol Drug Dev; 2019 Jul; 8(5):603-611. PubMed ID: 30256537
[TBL] [Abstract][Full Text] [Related]
20. Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy.
Navari RM; Rapoport BL; Powers D; Arora S; Clark-Snow R
Cancer Med; 2018 Jul; 7(7):2943-2950. PubMed ID: 29790666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
